Rigel Pharmaceuticals has launched a Phase II clinical trial to test the safety of fostamatinib to treat hospitalised Covid-19 patients.

The study is funded by the National Heart, Lung, and Blood Institute (NHLBI), a unit of the US National Institutes of Health (NIH), along with Inova Health System.

Fostamatinib is an oral inhibitor of spleen tyrosine kinase (SYK), which is associated with the intracellular signalling pathways of different immune cells and its inhibition could improve outcomes in Covid-19 patients.

Fostamatinib disodium hexahydrate tablets are approved in the US and Europe for adult chronic immune thrombocytopenia (ITP). The drug is available in the US under the brand name Tavalisse.

Rigel Pharmaceuticals president and CEO Raul Rodriguez said: “Based on our understanding of SYK’s role in the pathogenesis of the virus and fostamatinib’s mechanism of action, we believe expanding our clinical effort into this second trial in Covid-19 related lung injuries is critical.”

The randomised, double-blind, placebo-controlled Phase II trial will be conducted in about 60 patients at the NIH Clinical Center in Bethesda, Maryland, US, and Inova Fairfax Hospital.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It will involve patients who are a five to seven on the eight-point ordinal scale, meaning they need supplemental oxygen through a nasal cannula or non-invasive ventilation, mechanical ventilation or extracorporeal membrane oxygenation.

Oral treatment will be given twice daily for 14 days, with a follow-up period to day 60.

The primary objective is the safety of fostamatinib over placebo and the secondary objective is the early efficacy and clinically relevant disease progression measures.

Meanwhile, fostamatinib is also in a Phase II trial by Imperial College London to assess its efficacy as a potential treatment for Covid-19 pneumonia.

Earlier this month, the National Institutes of Health (NIH) launched two of three Phase III trials to investigate the safety and effectiveness of different blood thinners to treat adults with Covid-19.